UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or | --- | --- | --- | --- | --- | --- | |----------------------------------------------------------------------------|--------------------------------------------------------------------------------------|------------------------------------------------------------------------- ...

Exhibit 99.1 TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update Upcoming oral presentation for the ALLOHA TM Phase 1 heme trial at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition Company to host virtual KOL event featuring Ran Reshef, M.D., M.Sc., on Tuesday, December 10th at 8:00 a.m. ET to discuss clinical updates from the ALLOHA Phase 1 trial and heme development strategy On track to dose first patient with multiplex TCR-T therapy and ...

TScan Therapeutics, Inc. (TCRX) shares soared 7.6% in the last trading session to close at $5.69. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 5.4% loss over the past four weeks.The company is developing its lead TCR-T therapy candidates, TSC-100 and TSC-101, in an early-stage study for treating patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation. TScan is also deve ...

All TSC-treated patients were relapse-free and MRD negative as of data cutoff TSC-100 and TSC-101 demonstrate the potential to reduce relapse rates and increase relapse-free survival in patients with AML, ALL, or MDS undergoing allogeneic HCT with reduced intensity conditioning Company to host virtual KOL event featuring Ran Reshef, M.D., M.Sc., on Tuesday, December 10, at 8:00 a.m. ET WALTHAM, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology c ...

WALTHAM, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the acceptance of three abstracts for poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting being held November 6 – 10 in Houston, TX and virtually. Poster Presentation Details: Title: Disco ...

TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to loss of $0.51 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 6.67%. A quarter ago, it was expected that this company would post a loss of $0.25 per share when it actually produced a loss of $0.32, delivering a surprise of -28%. Over the last four quarters, the company has ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 | --- | --- | --- | --- | --- | --- | |--------------------------------------------------------------------------------------|-------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

Exhibit 99.1 TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update FDA grants RMAT designation to TSC-100 and TSC-101 for the treatment of patients with AML, ALL, and MDS undergoing allogeneic HCT with reduced intensity conditioning Engaged CDMO with global capabilities to support manufacturing for pivotal trials and commercialization On-track to report initial data from the solid tumor program and one-year data on initial patients in the ALLOHA TM Phase 1 heme trial ...

FDA grants RMAT designation to TSC-100 and TSC-101 for the treatment of patients with AML, ALL, and MDS undergoing allogeneic HCT with reduced intensity conditioning Engaged CDMO with global capabilities to support manufacturing for pivotal trials and commercialization On-track to report initial data from the solid tumor program and one-year data on initial patients in the ALLOHATM Phase 1 heme trial by the end of 2024 Cash, cash equivalents, and marketable securities continue to fund operations into the fo ...

Timothy Barberich retires as Chair; Stephen Biggar, M.D., Ph.D. assumes the role of Chair "We are pleased to welcome Garry to our Board of Directors. He has a breadth of experience in oncology development and commercialization spanning more than 35 years, including serving as president of Pfizer Oncology where he led its global oncology franchise," said Gavin MacBeath, Ph.D., Chief Executive Officer. "Garry has extensive expertise in operations, sales, regulatory strategy, and commercialization, and we look ...